Chemoinformaics analysis of
sesquicannabigerol
| Molecular Weight | 384.604 | nRot | 12 |
| Heavy Atom Molecular Weight | 344.284 | nRig | 9 |
| Exact Molecular Weight | 384.303 | nRing | 1 |
| Solubility: LogS | -3.937 | nHRing | 0 |
| Solubility: LogP | 9.45 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 68 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 28 | No. of Aromatic Carbocycles | 1 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 40 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 26 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 71.6957 |
| nHD | 2 | BPOL | 40.1283 |
| QED | 0.285 |
| Synth | 2.863 |
| Natural Product Likeliness | 1.656 |
| NR-PPAR-gamma | 0.942 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.782 |
| Pgp-sub | 0.002 |
| HIA | 0.006 |
| CACO-2 | -4.817 |
| MDCK | 0.0000177 |
| BBB | 0.128 |
| PPB | 0.976079 |
| VDSS | 11.172 |
| FU | 0.0355637 |
| CYP1A2-inh | 0.776 |
| CYP1A2-sub | 0.165 |
| CYP2c19-inh | 0.767 |
| CYP2c19-sub | 0.103 |
| CYP2c9-inh | 0.549 |
| CYP2c9-sub | 0.98 |
| CYP2d6-inh | 0.818 |
| CYP2d6-sub | 0.31 |
| CYP3a4-inh | 0.382 |
| CYP3a4-sub | 0.121 |
| CL | 10.908 |
| T12 | 0.084 |
| hERG | 0.072 |
| Ames | 0.006 |
| ROA | 0.017 |
| SkinSen | 0.949 |
| Carcinogencity | 0.081 |
| EI | 0.732 |
| Respiratory | 0.046 |
| NR-Aromatase | 0.734 |
| Antiviral | No |
| Prediction | 0.545008 |